Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of telisotuzumab adizutecan in MET-amplified advanced solid tumors
MOH_2025-09-07_014323Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telisotuzumab adizutecan in Nonhematologic neoplasms, sponsored by AbbVie Inc. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2025-09-07_014323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-07_014323.